Recent 8-K filings for RYTM

• May 5, 2026, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  Rhythm Q1 product revenue $60.1M; IMCIVREE HO launch >150 start forms; net loss $(0.83)/share

  Q1 2026 net product revenue $60.1M (up 5% sequentially); U.S. revenue $36.9M, ex-U.S. $23.2M.

• March 26, 2026, 7:59 PM ET regulatory materiality 0.70 positive item 7.01item 8.01item 9.01

  Rhythm Pharma gets positive CHMP opinion to expand IMCIVREE label for acquired hypothalamic obesity

  CHMP recommends expanding IMCIVREE (setmelanotide) marketing authorization to treat obesity/control hunger in patients >=4 years with acquired HO due to hypothalamic injury.

• March 20, 2026, 7:59 PM ET regulatory materiality 0.90 positive item 7.01item 8.01item 9.01

  Rhythm Pharma wins FDA approval for IMCIVREE in acquired hypothalamic obesity; Phase 3 shows -18.4% BMI reduction

  FDA approved IMCIVREE (setmelanotide) for acquired HO in adults and children 4+; first approved therapy for this indication.

• March 16, 2026, 7:59 PM ET other material materiality 0.85 negative item 7.01item 8.01item 9.01

  Rhythm's Phase 3 EMANATE trial misses primary endpoints; post hoc signals in POMC/SRC1

  Four substudies failed primary endpoint: placebo-adjusted BMI reductions of 4.3% (POMC/PCSK1), 3.6% (LEPR), 4.0% (SRC1), 1.7% (SH2B1); all p>0.05.

• March 2, 2026, 6:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Rhythm reports additional positive Phase 3 TRANSCEND data for setmelanotide in hypothalamic obesity

  Placebo-adjusted BMI reduction of 18.8% (N=142); primary endpoint met with -16.4% BMI change on setmelanotide vs +2.4% on placebo (p<0.0001).

• February 26, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Rhythm Pharmaceuticals Reports Q4 and Full Year 2025 Financial Results; IMCIVREE Revenue $57.3M in Q4

  Q4 2025 IMCIVREE revenue $57.3M, up 12% sequentially; full year revenue $194.8M vs $130.1M in 2024.

• January 9, 2026, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 8.01item 9.01

  Rhythm Pharma Q4 2025 IMCIVREE revenue ~$57M (+11% QoQ); FY2025 ~$194M (+50% YoY)

  Q4 2025 net product revenue ~$57M, up 11% sequentially from Q3 2025.

• December 11, 2025, 6:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Rhythm Pharma reports positive Phase 2 setmelanotide data in PWS; plans Phase 3

  18 patients enrolled; 17 remain on therapy; safety consistent with known profile.

• November 7, 2025, 6:59 PM ET regulatory materiality 0.65 neutral item 7.01item 8.01item 9.01

  FDA extends review of Rhythm's setmelanotide sNDA to March 20, 2026

  New PDUFA goal date March 20, 2026, extended 3 months from December 20, 2025.

• November 4, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Rhythm Q3 IMCIVREE revenue $51.3M; net loss -$0.82/sh; PDUFA Dec 20

  Q3 2025 IMCIVREE revenue $51.3M (+6% seq, +54% YoY); US $38.2M (+19% seq).

• August 5, 2025, 7:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Rhythm Pharma Q2 revenue $48.5M (+29% seq), net loss $(48.0M); advances setmelanotide filings for AHO

  Q2 net product revenue $48.5M, up 29% sequentially from Q1 2025; US revenue $32.0M (66% of total), up 31%.

• July 11, 2025, 7:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  Rhythm Pharmaceuticals raises $188.7M in public equity offering; underwriters exercise full option

  Offering of 2,058,824 shares at $85.00 per share; underwriters exercised 30-day option for 308,823 additional shares in full.

• July 9, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Rhythm Pharma's bivamelagon Phase 2 meets endpoints: -9.3% BMI reduction at 14 weeks

  BMI reduction -9.3% (600mg, p=0.0004) and -7.7% (400mg, p=0.0002) vs 2.2% increase on placebo.

• May 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Rhythm Q1 product rev $37.7M; Phase 3 HO trial meets endpoint with -19.8% BMI reduction

  Net product revenue $37.7M, up from $26.0M YoY; U.S. $24.5M, ex-U.S. $13.2M.

• April 7, 2025, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Rhythm Pharma Phase 3 TRANSCEND trial meets primary endpoint with -19.8% placebo-adjusted BMI reduction in 120 patients

  Mean BMI change of -16.5% on setmelanotide vs +3.3% for placebo at 52 weeks (p<0.0001); 80% achieved ≥5% BMI reduction.

• March 20, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.02item 1.01item 7.01item 9.01

  Rhythm terminates RareStone license for IMCIVREE in China; reacquires rights for $6.3M

  Termination of 2021 Exclusive License and Share Purchase agreements with RareStone Group Ltd.

• February 26, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Rhythm Q4 2024 IMCIVREE revenue $41.8M; cash runway extended to 2027

  Q4 2024 IMCIVREE net revenue $41.8M (+26% sequential, +73% YoY); FY2024 total $130.1M.

• January 10, 2025, 6:59 PM ET other material materiality 0.75 positive item 2.02item 7.01item 8.01item 9.01

  Rhythm Pharma reports preliminary 2024 IMCIVREE sales of $130M, up 68% YoY; Phase 3 HO data on track for H1 2025

  Preliminary Q4 2024 IMCIVREE net revenues of ~$42M, up 26% sequentially; full year ~$130M vs $77.4M in 2023.

• November 5, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Rhythm Pharma Q3 revenue $33.3M (+14% seq); FDA Priority Review for label expansion to age 2

  IMCIVREE net revenue $33.3M (Q3 2024), up 48% YoY from $22.5M; US sales $23.3M (+8% seq), ex-US $10.0M (+35% seq).

• August 6, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Rhythm Pharma Q2 2024 revenue $29.1M, up 52% YoY; net loss narrows to $33.6M

  Net product revenue $29.1M vs $19.2M in Q2 2023; 74% generated in United States.

• May 7, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  Rhythm Pharma Q1 net revenue $26.0M (+126% YoY); net loss $141.4M on $92.4M LB54640 charge

  Net product revenue $26.0M (Q1 2023: $11.5M); 74% from U.S. sales.

• April 16, 2024, 7:59 PM ET debt materiality 0.70 neutral item 1.01item 3.03item 5.03item 8.01item 9.01 ◈ Governance Changes◈ Material Agreements

  Rhythm Pharmaceuticals closes $150M Series A Convertible Preferred issuance to Perceptive affiliates

  Closed on April 15, 2024; issued 150,000 shares at $1,000 each for aggregate $150,000,000.

• April 1, 2024, 7:59 PM ET other material materiality 0.75 positive item 1.01item 3.02item 8.01item 9.01 ◈ Material Agreements

  Rhythm Pharma raises $150M in convertible preferred stock; conversion at $48 (19% premium)

  $150M gross proceeds from sale of Series A Convertible Preferred Stock to Perceptive and other existing shareholders.

• February 29, 2024, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01

  Rhythm Pharmaceuticals amends sales agreement to allow up to $200M in at-the-market stock offerings

  Amendment increases ATM offering limit from $100M to $200M, excluding $50M already sold.

• February 22, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 8.01item 9.01 ◈ Earnings Releases

  Rhythm Pharma Q4 IMCIVREE rev $24.2M; reports material weakness in IT controls

  Q4 2023 net product revenue $24.2M (FY2023 $77.4M) vs $8.8M Q4 2022; net loss $41.6M ($0.70/share).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.70 · Most common event other_material

13 positive 2 negative 17 neutral

source · RYTM on sec.gov